WT1 and acute myeloid leukemia: The Wilms’ tumor 1 (WT1) gene, whose protein product acts as a transcription factor, regulating cell development and survival and whose quantitative assessment is a useful tool to measure disease burden in AML [14,27,28], was overexpressed in either the peripheral blood or bone marrow in 17 of 19 (89.5%) evaluable BCL-2− AML patients and in 57 of 60 (95.0%) evaluable BCL-2+ AML patients.